MSTN and sarcopenia: bimagrumab treatment, a monoclonal antibody that blocks activin type II receptor (ActRII) to inhibit myostatin signaling and stimulate protein anabolism was added to optimized standard of care in community‐dwelling older adults with sarcopenia [20].